Meeting
2023 ASCO Annual Meeting
Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
Authors
Avina Rami
Harvard Medical School, Boston, MA
Avina Rami , Steven G. DuBois , Kevin M. Campbell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3149)
DOI
10.1200/JCO.2023.41.16_suppl.3149
Abstract #
3149
Poster Bd #
347
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Utilizing Drug Combo to improve the design of phase 1 trials for anticancer drugs.
First Author: Lei Wang
Poster
2023 ASCO Annual Meeting
Phase 1 trial of avelumab with hypofractionated thoracic radiation therapy (HT-RT) in patients with metastatic soft-tissue sarcomas (mSTS).
First Author: Shane H Zaidi
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens